Treatment with pioglitazone induced significant, reversible mitral regurgitation
(2008) In Cardiovascular Diabetology 7(12).- Abstract
- There has in recent years been great concern about possible cardiac side effects of thiazolidinediones ( TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1200342
- author
- Dorkhan, Mozhgan LU ; Dencker, Magnus LU and Frid, Anders
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cardiovascular Diabetology
- volume
- 7
- issue
- 12
- article number
- 3 pp
- publisher
- BioMed Central (BMC)
- external identifiers
-
- wos:000256681600001
- scopus:44949243029
- ISSN
- 1475-2840
- DOI
- 10.1186/1475-2840-7-12
- language
- English
- LU publication?
- yes
- id
- df120ebf-0140-4946-8b19-a08b3f60f0b2 (old id 1200342)
- date added to LUP
- 2016-04-01 13:22:37
- date last changed
- 2024-01-09 12:45:20
@article{df120ebf-0140-4946-8b19-a08b3f60f0b2,
abstract = {{There has in recent years been great concern about possible cardiac side effects of thiazolidinediones ( TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.}},
author = {{Dorkhan, Mozhgan and Dencker, Magnus and Frid, Anders}},
issn = {{1475-2840}},
language = {{eng}},
number = {{12}},
publisher = {{BioMed Central (BMC)}},
series = {{Cardiovascular Diabetology}},
title = {{Treatment with pioglitazone induced significant, reversible mitral regurgitation}},
url = {{http://dx.doi.org/10.1186/1475-2840-7-12}},
doi = {{10.1186/1475-2840-7-12}},
volume = {{7}},
year = {{2008}},
}